Premed · Premed · Genetics
Lecture 26: Ethics in Genetics
Genetics
Learning Objectives
By the end of this lecture, students will be able to:
- Apply the four principles of biomedical ethics (autonomy, beneficence, non-maleficence, justice) to genetics scenarios
- Discuss the ethical issues surrounding genetic testing, including the right to know and not to know
- Explain the legal protections against genetic discrimination (GINA and its limitations)
- Evaluate the ethical challenges of germline genome editing and its distinction from somatic editing
- Discuss the ethical implications of direct-to-consumer genetic testing, genetic data privacy, and biobanking
- Analyze the ethics of prenatal genetic testing, selection, and reproductive technologies
Lecture Content
I. Ethical Frameworks in Genetics
Four principles of biomedical ethics (Beauchamp and Childress): Autonomy: respect individuals' right to make informed decisions about their own genetic information and health. Beneficence: act in the best interest of the patient; use genetic information to improve health outcomes. Non-maleficence: do no harm; avoid causing psychological, social, or economic harm through genetic information. Justice: ensure fair and equitable access to genetic testing, counseling, and therapies across all populations. Additional ethical principles relevant to genetics: Privacy and confidentiality: genetic information is uniquely personal and familial. Informed consent: particularly important given the complexity and implications of genetic information. Genetic exceptionalism: the debate over whether genetic information is fundamentally different from other medical information and deserves special protections. Solidarity and reciprocity: in the context of research participation and data sharing.
II. Ethical Issues in Genetic Testing
Right to know vs. right not to know: Individuals have the right to access their genetic information. They also have the right to decline genetic testing or to not receive results. Tension arises when a family member's test result reveals information about relatives who may not want to know. Example: presymptomatic testing for Huntington disease — a positive result in a grandchild may reveal the parent's status (who may not want to know) Incidental and secondary findings: WES/WGS may reveal variants unrelated to the primary indication (incidental findings) ACMG recommends reporting pathogenic/likely pathogenic variants in a list of ~80 genes associated with actionable conditions (ACMG SF v3.2) regardless of the primary indication. Patients should be counseled about the possibility of incidental findings before testing. Debate: should all incidental findings be reported? Should patients be able to opt out? Testing in minors: Generally, genetic testing of children is recommended only when results will directly affect medical management in childhood. Predictive testing for adult-onset conditions (e.g., Huntington disease, BRCA) should be deferred until the child can provide autonomous consent. Exception: conditions with childhood-onset surveillance or prevention strategies (e.g., FAP, hereditary cancer syndromes with childhood risk) Carrier testing in children is generally deferred to adulthood. Duty to warn at-risk relatives: When a patient is diagnosed with a hereditary condition, should the physician/counselor inform at-risk relatives? Patient confidentiality vs. duty to warn. Most guidelines recommend encouraging the patient to inform relatives rather than breaking confidentiality. Legal precedent varies by jurisdiction (Tarasoff duty vs. genetic privacy laws).
<image>Panel A: The four principles of biomedical ethics applied to a genetic testing scenario — a central diagram with four quadrants (autonomy, beneficence, non-maleficence, justice), each containing a specific genetic testing example: autonomy (patient's right to refuse BRCA testing), beneficence (offering newborn screening for treatable conditions), non-maleficence (avoiding predictive testing in children for adult-onset untreatable conditions), justice (ensuring equal access to genetic counseling regardless of socioeconomic status). Panel B: Decision flowchart for incidental findings management — starting from WES/WGS performed for a primary indication, discovery of a secondary finding, assessment against the ACMG recommended gene list, patient preference regarding receiving secondary findings, and the possible outcomes (report, do not report, refer for genetic counseling). Panel C: Ethical tension diagram for duty to warn — a triangle showing the patient (with confidentiality rights), the at-risk relative (with a potential health benefit from knowing), and the clinician (with duties to both), illustrating the competing ethical obligations and the recommended approach of encouraging family communication.</image>
III. Genetic Discrimination and Legal Protections
Genetic discrimination: the use of genetic information to discriminate against individuals in employment, insurance, or other domains. GINA (Genetic Information Nondiscrimination Act, 2008, US): Title I: prohibits health insurers from using genetic information for coverage or premium decisions. Title II: prohibits employers (with 15+ employees) from using genetic information in hiring, firing, or employment decisions. Limitations of GINA: Does NOT cover life insurance, disability insurance, or long-term care insurance. Does NOT apply to the military, Indian Health Service, or very small employers. Does NOT apply once a condition has been diagnosed (only protects pre-symptomatic genetic information) Enforcement and awareness remain limited. International protections vary widely: Canada: Genetic Non-Discrimination Act (2017) EU: GDPR provides broad data protections applicable to genetic data. Many countries lack specific genetic discrimination legislation. Impact on patient decisions: fear of genetic discrimination can deter individuals from undergoing beneficial genetic testing. Genetic counselors routinely discuss the protections and limitations of GINA. Employer wellness programs: raising concerns about potential misuse of genetic information. Law enforcement use of genetic data: familial DNA searching in criminal databases, use of consumer genomic databases (GEDmatch, FamilyTreeDNA) to identify suspects — raises concerns about consent, privacy, and civil liberties.
IV. Ethics of Genome Editing
Somatic gene editing: modifications in non-reproductive cells; not heritable. Ethical considerations similar to other medical therapies: safety, efficacy, informed consent, access. Generally accepted within the standard regulatory framework for gene therapy. Examples: CRISPR therapy for sickle cell disease (CASGEVY), CAR-T cell therapy. Germline gene editing: modifications in sperm, eggs, or embryos; heritable across generations. Ethical concerns: Safety: off-target effects could introduce harmful mutations transmitted to all future generations. Consent: future individuals cannot consent to heritable genetic changes. Medical necessity: alternative approaches exist (PGT, prenatal diagnosis, carrier screening) Slippery slope to enhancement: correction of disease vs. enhancement of traits (intelligence, appearance, athletic ability) — where is the line? Equity and justice: expensive technologies may be accessible only to the wealthy, exacerbating social inequalities. Eugenics concerns: historical abuses of eugenic programs raise alarm about any technology that enables selection of genetic traits. He Jiankui case (2018): created the first germline-edited human babies (CCR5 gene editing for claimed HIV resistance) Widely condemned by the scientific community. Violations of ethical norms: inadequate informed consent, no clear medical necessity, premature use of technology. He Jiankui was sentenced to prison in China. Prompted international calls for moratorium on heritable genome editing. Current consensus: no clinical application of germline genome editing until safety, ethical, and societal issues are resolved; broad international dialogue is needed. WHO Expert Advisory Committee (2021): recommended governance framework but did NOT call for a blanket ban.
V. Direct-to-Consumer Genetic Testing and Data Privacy
Direct-to-consumer (DTC) genetic testing: tests marketed directly to consumers without a healthcare provider intermediary (e.g., 23andMe, AncestryDNA) Types of information provided: ancestry, carrier status for select conditions, pharmacogenomic variants, trait reports, health risk assessments. Ethical concerns: Accuracy and interpretation: analytical validity may be high, but clinical validity and utility for many results are limited. Lack of genetic counseling: results may be misinterpreted without professional guidance. Psychological impact: anxiety, false reassurance, unexpected findings (non-paternity, previously unknown relatives) Privacy: genetic data is shared with the company and may be used for research, sold to third parties, or accessed by law enforcement. Informed consent for research: many DTC companies use customer data for research — consent processes vary in transparency. Genetic data privacy: Genetic data is uniquely identifying (cannot be de-identified — re-identification is possible) Data breaches could expose sensitive health and ancestry information. Genetic data implicates relatives who have not consented to testing. Calls for stronger regulation of genetic data use, storage, and sharing.
<image>Panel A: Timeline of key events in the ethics of genome editing — discovery of CRISPR-Cas9 (2012), first National Academy of Sciences summit on human gene editing (2015), He Jiankui announcement of germline-edited babies (2018), WHO governance framework (2021), and ongoing international dialogue; each event is annotated with the key ethical discussion point raised. Panel B: Somatic vs. germline editing ethical comparison — a two-column diagram contrasting somatic editing (affects only the patient, not heritable, standard regulatory framework, widely accepted for medical use) with germline editing (heritable, affects future generations, cannot obtain consent from future persons, risk of enhancement, currently subject to moratorium in most countries). Panel C: DTC genetic testing data flow diagram — showing the consumer providing a saliva sample, the company genotyping and analyzing the data, results returned to the consumer, and the potential downstream uses of the data (internal research, third-party partnerships, law enforcement requests, data breaches), with ethical concerns flagged at each point.</image>
VI. Ethics of Prenatal and Reproductive Genetics
Prenatal genetic testing: NIPT can detect trisomy 21 (Down syndrome) with high sensitivity → raises questions about selective termination. In countries with widespread prenatal screening, birth rates of individuals with Down syndrome have declined significantly. Disability rights perspective: prenatal selection against genetic conditions sends a message that lives with disability are less valued. Reproductive autonomy perspective: parents have the right to make informed reproductive decisions. Preimplantation genetic testing (PGT): Selecting embryos raises questions: which conditions justify selection? Should PGT be used for non-medical traits? "Savior siblings": selecting an embryo that is an HLA match for a sick sibling (for stem cell donation) Sex selection for non-medical reasons: prohibited in some countries, permitted in others. Expansion of newborn screening: as genomic sequencing becomes cheaper, should all newborns be sequenced? Benefits: early detection of all genetic conditions. Concerns: incidental findings, information overload, parental anxiety, impact on child's future autonomy. Genetic enhancement and social justice: As knowledge grows, the possibility of genetic enhancement raises fundamental questions about fairness, human identity, and what it means to be "normal". No current capacity for meaningful genetic enhancement of complex traits, but the ethical frameworks must be developed proactively.
VII. Moving Forward: Responsible Genetics
Ongoing dialogue between scientists, clinicians, ethicists, policymakers, patients, and the public is essential. Ethical frameworks must evolve alongside rapidly advancing genetic technologies. Key priorities: Equitable access to genetic technologies across socioeconomic and racial/ethnic groups. Inclusive representation in genetic research cohorts. Robust legal protections against genetic discrimination. Transparent governance of genetic data. Continuous public engagement and education about genetics.
